- Factor V Leiden
- Prothrombin 20210
- Antiphospholipid Syndrome
- Others
Hypercoagulability Market was valued at USD 652 million in 2022 and is poised to grow at a CAGR of 6.4% over 2023-2029. Hypercoagulability, also known as thrombophilia, is an abnormality of blood coagulation that increases the risk of thrombosis, and the most common conditions associated with thrombophilia are deep vein thrombosis and pulmonary embolism, which are collectively known as venous thromboembolism. According to the Europe PMC, venous thromboembolism has an incidence ranging between 1 and 5 in 1000 per year in the general population. The rising cases of hypercoagulability risk factors such as cancers and heart diseases are driving the hypercoagulability market growth. whereas, the cost of treatment might hinder the market growth. The initiatives by governments and non-government organizations will act as an opportunity for the market to expand.
Hypercoagulability Market Key Developments:
In May 2020, the US FDA approved Deciphera Pharmaceuticals’s Qinlock (Ripretinib) tablets for advanced gastrointestinal stromal tumors.
Hypercoagulability Market Summary
Study Period
2023-29
Base Year
2022
CAGR
6.4%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Hypercoagulability Market Dynamics
Due to various initiatives from pharmaceutical companies and government organizations, and the increasing risk factors of hypercoagulability, there will be a positive impact on market growth. For instance, in July 2022, the National Blood Clot Alliance established the Council for Emerging Researchers in Thrombosis to serve as a forum for researchers working in thrombosis and thrombophilia to promote and carry out research and scientific activities. However, accessibility to primary care for the patients could pose a hindrance to the market growth.
North-America Got Significant Share of
Hypercoagulability Market Regional Analysis
The hypercoagulability market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. As per the Europe PMC, the incidence rate for venous thromboembolism is 1 per 1,00,000 per year in children and increases to 1 per 1000 per year in adults. According to a study report, factor V Leiden is present in 5% of the population of Northern European descent, and the prothrombin mutation occurs at rates of 1-4% in the general population. The Asia Pacific Hypercoagulability market is expected to dominate the market over the forecast period, owing to the growing healthcare infrastructure and the rising prevalence of the patient population in the region. The North America market is also expected to hold a large share of the market due to the presence of key players in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The hypercoagulability market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Hypercoagulability Market Segmentation
By Type
By Drug Class
- Heparin
- Warfarin
- Vitamin K Antagonist
- Direct Thrombin Inhibitors
- Others
By Route of Administration
- Oral
- Injectable
By End User
- Hospitals
- Specialty Clinics
- Homecare
- Others
Frequently Asked Questions
The Hypercoagulability market was valued at USD 652 million in 2022 and is expected to grow at a 6.4% CAGR over the forecast period 2023 – 2029.
The initiatives by governments and non-government organizations are the key opportunities for the Hypercoagulability market.
The rising cases of hypercoagulability risk factors such as cancers and heart diseases are the growth drivers in the Hypercoagulability market.
Yino Pharma Limited, Sanofi, Teva Pharmaceutical Industries Ltd., Shenzhen Hepalink Pharmaceutical, Techdow Pharmaceutical Co., Ltd., Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Novartis AG, Nanjing Jianyo, Biochemical Pharmaceutical Co., Ltd., Hikma Pharmaceuticals PLC, Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Fresenius Kabi AG, Eisai Co., Ltd., and Aspen Holdings are a few companies operating in the Hypercoagulability market.
- Yino Pharma Limited
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Shenzhen Techdow Pharmaceutical Co., Ltd.
- Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Novartis AG
- Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.
- Hikma Pharmaceuticals PLC
- Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
- Fresenius Kabi AG
- Eisai Co., Ltd.
- Aspen Holdings
- Mylan N.V.
- Hoffmann-La Roche Ltd.
- Pfizer Inc.